Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4076
Hurco Companies Inc
HURC
$144M
| $298K | ﹤0.01% |
19,281
+323
| +2% | +$5.35K |
|
4077
LifeVantage
LFVN
$82.1M
| $297K | ﹤0.01% |
48,251
+12,883
| +36% | +$95.4K |
|
|
CMDB
4078
Costamare Bulkers Holdings
CMDB
$429M
| $297K | ﹤0.01% |
19,277
+1,453
| +8% | +$21K |
|
4079
Immersion
IMMR
$247M
| $297K | ﹤0.01% |
43,679
-4,268
| -9% | -$29K |
|
4080
Quantum-Si Incorporated
QSI
$182M
| $296K | ﹤0.01% |
269,415
+48,205
| +22% | +$78.5K |
|
4081
Immatics
IMTX
$1.33B
| $296K | ﹤0.01% |
28,185
+2,874
| +11% | +$29K |
|
4082
Virginia National Bankshares
VABK
$257M
| $295K | ﹤0.01% |
7,415
+710
| +11% | +$28.4K |
|
4083
Kingstone Companies
KINS
$284M
| $295K | ﹤0.01% |
17,531
+1,484
| +9% | +$22.6K |
|
4084
Rimini Street
RMNI
$445M
| $294K | ﹤0.01% |
75,893
+7,271
| +11% | +$30.2K |
|
4085
Ohio Valley Banc Corp
OVBC
$211M
| $294K | ﹤0.01% |
7,364
+1,983
| +37% | +$74.7K |
|
4086
Weyco Group
WEYS
$446M
| $294K | ﹤0.01% |
9,615
+869
| +10% | +$26.6K |
|
4087
Protara Therapeutics
TARA
$219M
| $293K | ﹤0.01% |
55,057
+9,537
| +21% | +$53K |
|
4088
Relmada Therapeutics
RLMD
$503M
| $290K | ﹤0.01% |
60,000
+50,000
| +500% | +$168K |
|
4089
Core Molding Technologies
CMT
$224M
| $290K | ﹤0.01% |
14,448
+695
| +5% | +$13.3K |
|
4090
CALL
Illumina
ILMN
$29.1B
| $289K | ﹤0.01% |
2,200
| – | – |
|
4091
Lantronix
LTRX
$275M
| $288K | ﹤0.01% |
49,069
+37,634
| +329% | +$196K |
|
|
DAWN
4092
CALL
DELISTED
Day One Biopharmaceuticals
DAWN
| $287K | ﹤0.01% |
+30,800
| New | +$257K |
|
4093
iShares MSCI Taiwan ETF
EWT
$11.4B
| $285K | ﹤0.01% |
4,479
-12,121
| -73% | -$780K |
|
|
GLIBA
4094
Liberty Capital Corp Series A GCI Group Common Stock
GLIBA
$1.03B
| $284K | ﹤0.01% |
7,704
+7,661
| +17,816% | +$269K |
|
4095
MediWound
MDWD
$179M
| $282K | ﹤0.01% |
15,276
+3,747
| +33% | +$68.5K |
|
4096
Quad
QUAD
$507M
| $282K | ﹤0.01% |
44,971
+4,265
| +10% | +$25.1K |
|
4097
Fennec Pharmaceuticals
FENC
$414M
| $282K | ﹤0.01% |
36,597
+3,559
| +11% | +$29.2K |
|
4098
iQIYI
IQ
$1.28B
| $281K | ﹤0.01% |
146,552
+61,825
| +73% | +$132K |
|
4099
CALL
Quantum Computing Inc
QUBT
$2.02B
| $281K | ﹤0.01% |
+27,400
| New | +$390K |
|
4100
The Joint Corp
JYNT
$123M
| $281K | ﹤0.01% |
32,235
+1,623
| +5% | +$13.8K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.